Scholarlink

<p>Pain remains a major clinical challenge due to its complex and multifactorial nature. The available treatments, such as conventional analgesics and opioids, often fail to provide adequate relief and are associated with limitations, including cardiovascular toxicity and short duration of action. This scenario reinforces the urgent need for safer and more effective therapeutic approaches. Cannabidiol (CBD) has emerged as a promising alternative in the pain management. Nanoencapsulation based on nanostructured lipid carriers (NLC) offers a potential strategy to overcome these limitations. In this work, CBD oil was encapsulated in NLC (NLC/CBD; 5.0%), resulting in a formulation that remained stable for 365 days at 25&#xa0;°C. In vivo tests using chicken embryos indicated no toxicity of NLC/CBD at concentrations ranging from 0.72 to 2.87&#xa0;mg/mL. Furthermore, the analgesia of NLC/CBD (1.0&#xa0;mg/mL) was confirmed on <i>Drosophila melanogaster</i> alternative biological model. These findings suggested that the herbal-based NLC loading CBD could represent a cheap, long-term stable, biocompatible and efficient nanosystem for pain management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cannabidiol-based lipid nanocarriers with analgesic activity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月19日

查看全文
  • Arissa de Oliveira Sato,
  • João Pedro Tánnus Goulart,
  • Tamiris Sabrina Rodrigues,
  • Carlos Ueira-Vieira,
  • Luciana Machado Bastos,
  • Simone Sommerfeld,
  • Belchiolina Beatriz Fonseca,
  • Lígia Nunes de Morais Ribeiro

摘要

Pain remains a major clinical challenge due to its complex and multifactorial nature. The available treatments, such as conventional analgesics and opioids, often fail to provide adequate relief and are associated with limitations, including cardiovascular toxicity and short duration of action. This scenario reinforces the urgent need for safer and more effective therapeutic approaches. Cannabidiol (CBD) has emerged as a promising alternative in the pain management. Nanoencapsulation based on nanostructured lipid carriers (NLC) offers a potential strategy to overcome these limitations. In this work, CBD oil was encapsulated in NLC (NLC/CBD; 5.0%), resulting in a formulation that remained stable for 365 days at 25 °C. In vivo tests using chicken embryos indicated no toxicity of NLC/CBD at concentrations ranging from 0.72 to 2.87 mg/mL. Furthermore, the analgesia of NLC/CBD (1.0 mg/mL) was confirmed on Drosophila melanogaster alternative biological model. These findings suggested that the herbal-based NLC loading CBD could represent a cheap, long-term stable, biocompatible and efficient nanosystem for pain management.